Liquidia Technologies is a US based biopharmaceutical company that has developed a solution termed as PRINT technology to design drug particles in any number of compositions, sizes, or shapes. According to the company's website, PRINT technology could be a novel approach to drug development and production as it allows precise engineering of drug particles.

The PRINT technology is under clinical development for inhaled diseases, pain management and ophthalmology. Liquidia has also partnered with GlaxoSmithKline to expand the applications of PRINT technology.

Liquidia Technologies website states that PRINT technology integrates a proprietary particle molding technology with a modular, roll-to-roll manufacturing process to deliver scalable processes that meet cGMP requirements. The technology incorporates production practices from the semiconductor and materials industries. Through this approach, Liquidia and its partners can achieve a high level of control over the physical and chemical characteristics of the particle.

Liquidia Technologies is applying its PRINT technology toward internal, licensed, and co-development opportunities, including internal development of LIQ861 for inhaled and LIQ865 for pain relief and a treatment for glaucoma through spin-out company Envisia Therapeutics

Recently, Liquidia Technologies appointed Arthur S. Kirsch to its board of directors and named him Chairman of the audit committee.

"We are very pleased with the appointment of Arthur, a well-respected investment banking executive and established strategic advisor, to Liquidia's board," said Seth Rudnick, Chairman of Liquidia Board of Directors. "We look forward to working with Arthur and believe his vast financial experience that spans across public and private companies, M&A and global markets will be a valuable asset to our board and management team in the years to come."